Core Laboratories Inc [CLB] stock is trading at $16.86, saw in change for the day. An important factor to consider is whether the stock is rising or falling in short-term value. The CLB shares have gain 42.28% over the last week, with a monthly amount glided 31.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Core Laboratories Inc [NYSE: CLB] stock has seen the most recent analyst activity on March 12, 2025, when Citigroup upgraded its rating to a Neutral and also boosted its price target to $16 from $15. Previously, Citigroup downgraded its rating to Sell on June 30, 2023, and dropped its price target to $21. On April 18, 2023, downgrade downgraded it’s rating to Underperform but maintained its price target of $21.50 on the stock. BofA Securities upgraded its rating to a Neutral. Citigroup upgraded its rating to a Neutral and reduced its price target to $17 on October 07, 2022. Morgan Stanley downgraded its rating to Underweight for this stock on September 26, 2022, but kept the price target unchanged to $20. In a note dated April 18, 2022, Piper Sandler downgraded an Underweight rating on this stock and boosted its target price from $19.50 to $21.30.
Core Laboratories Inc [CLB] stock has fluctuated between $9.72 and $21.83 over the past year. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Core Laboratories Inc [NYSE: CLB] shares were valued at $16.86 at the most recent close of the market. An investor can expect a potential return of 48.28% based on the average CLB price forecast.
Analyzing the CLB fundamentals
Core Laboratories Inc [NYSE:CLB] reported sales of 517.50M for the trailing twelve months, which represents a growth of 0.09%. Gross Profit Margin for this corporation currently stands at 0.17% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.12 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.50 points at the first support level, and at 16.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.34, and for the 2nd resistance point, it is at 17.82.
Ratios To Look Out For
For context, Core Laboratories Inc’s Current Ratio is 2.37. On the other hand, the Quick Ratio is 1.76, and the Cash Ratio is 0.27. Considering the valuation of this stock, the price to sales ratio is 1.52, the price to book ratio is 2.86 and price to earnings (TTM) ratio is 24.84.
